BVI appoints Jim Hollingshead as CEO

Core Insights - BVI has appointed Jim Hollingshead, former CEO of Insulet, as its new President and CEO, succeeding Shervin Korangy [1][3][7] - The leadership change follows BVI's successful capital raise of $1 billion last year, aimed at accelerating product innovation and expanding its global presence [3] - BVI specializes in ophthalmic devices, particularly products for cataract and retina surgeries, with manufacturing sites in China, Europe, Mexico, and the U.S. [3] Company Background - BVI, originally known as Beaver-Visitec International, was created by RoundTable Healthcare Partners through the acquisition of ophthalmology products from Aspen Surgical, BD, and Medtronic [4] - TPG Capital acquired BVI from RoundTable in 2016, and since then, BVI has expanded its intraocular lens market presence by acquiring PhysIOL Group and Benz Research & Development [5] - BVI launched its first intraocular lens, the monofocal IPure, in the U.S. in 2020, and received FDA approval for its Finevision HP trifocal intraocular lens last year [5][6] Product Development - The approval of the Finevision HP lens has solidified BVI's global leadership in premium intraocular lenses for U.S. patients, with a history of use in the European Union since 2010 [6] - Competitors in the intraocular lens market include Alcon, Bausch & Lomb, and Johnson & Johnson [6]